Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 12/20 | 0.80 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.68 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11637763 | 1.00 | MTNR1B (0.80) | MTNR1BMTNR1APGRXIAPAR | |
| SCHEMBL11645644 | 0.90 | MTNR1B (0.65) | MTNR1BMTNR1AALDH1A1TP53TSHR | |
| SCHEMBL11642716 | 0.89 | MTNR1B (0.64) | MTNR1BMTNR1AXIAPALDH1A1RAF1 | |
| SCHEMBL11645905 | 0.89 | XIAP (0.62) | MTNR1BMTNR1AXIAPALDH1A1TP53 | |
| SCHEMBL11644316 | 0.86 | LTA4H (0.62) | MTNR1BMTNR1AXIAPALDH1A1RAF1 | |
| SCHEMBL11641056 | 0.86 | MTNR1B (0.60) | MTNR1BMTNR1AXIAPALDH1A1RAF1 | |
| SCHEMBL11642853 | 0.86 | XIAP (0.70) | MTNR1BPGRXIAPALDH1A1LTA4H | |
| SCHEMBL15623783 | 0.85 | XIAP (0.68) | MTNR1BXIAPALDH1A1LTA4H | |
| SCHEMBL11648371 | 0.85 | XIAP (0.63) | MTNR1BMTNR1AXIAPLTA4H | |
| SCHEMBL11642384 | 0.84 | MTNR1B (0.61) | MTNR1BMTNR1AXIAPALDH1A1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-11-29 | — | — | US | disclosed |
| US-10058551-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-08-28 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9849131-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20140206713-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8722695-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-05-13 | — | — | US | disclosed |
| US-8722695-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-05-13 | — | — | US | disclosed |
| US-8722695-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-05-13 | — | — | US | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| EP-2509961-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | Autifony Therapeutics Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011069951-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011069951-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | MTNR1B 1903/4885MTNR1A 2267/4885PGR 3975/4885 |
| US-20180021336-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | MTNR1B 1903/4885MTNR1A 2267/4885PGR 3975/4885 |
| US-10632118-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | MTNR1B 1903/4885MTNR1A 2267/4885PGR 3975/4885 |
| US-10058551-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | MTNR1B 1903/4885MTNR1A 2267/4885PGR 3975/4885 |
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | MTNR1B 1903/4885MTNR1A 2267/4885PGR 3975/4885 |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | MTNR1B 1146/4885MTNR1A 1433/4885PGR 3761/4885 |
| US-20140206713-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | MTNR1B 323/4885MTNR1A 571/4885PGR 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.